Last reviewed · How we verify
NCT03326492: ESAA
Evaluation of Anti-venoms Serum in Africa
trial testing Antivenom serum Inoserp Pan-Africa® injection in Snake Bites in 474 participants. Completed in 14 September 2021.
14 September 2021
Quick facts
| Lead sponsor | Institut Pasteur |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 474 |
| Start date | 17 October 2019 |
| Primary completion | 14 September 2021 |
| Estimated completion | 14 September 2021 |
| Sites | 13 locations across Cameroon |
Drugs / interventions tested
- Antivenom serum Inoserp Pan-Africa® injection — full drug profile →
Conditions studied
- Snake Bites — all drugs for Snake Bites →
- Antivenins — all drugs for Antivenins →
- Snake Venoms — all drugs for Snake Venoms →
Sponsor
Institut Pasteur — full company profile →
Who can join
5 and older, any sex, with Snake Bites or Antivenins. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
There is little or no assessment under real-use conditions of the efficacy and the tolerance in the short, medium and long term of the antivenoms currently on the market and used in the treatment of snake bites. The main objective is to assess the short term tolerance (\< 2 hours post-injection) of the antivenom Inoserp Pan-Africa® (temporary market authorization) from Inosan laboratory currently available in Cameroon.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Real life condition evaluation of Inoserp PAN-AFRICA antivenom effectiveness in Cameroon.
Chippaux JP, Ntone R, Benhammou D, Madec Y, et al · · 2023 · cited 6× · PMID 37939111 · DOI 10.1371/journal.pntd.0011707 -
Snakebites in Cameroon: Tolerance of a Snake Antivenom (Inoserp™ PAN-AFRICA) in Africa in Real-Life Conditions.
Benhammou D, Chippaux JP, Ntone R, Madec Y, et al · · 2024 · cited 4× · PMID 38668590 · DOI 10.3390/toxins16040165 -
Epidemiologic, clinical, and therapeutic aspects of formally identified Echis romani bites in northern Cameroon.
Chippaux JP, Amta P, Madec Y, Ntone R, et al · · 2025 · PMID 40720423 · DOI 10.1371/journal.pntd.0013195
Verify or expand the search:
- PubMed search for NCT03326492
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Institut Pasteur trials
Trials by the same sponsor.
- NCT07205913 — Gut Microbiota, Diet-INDuced Obesity and Type 2 Diabetes in New Caledonia - MIND · not yet recruiting
- NCT06945822 — Characterizing the Host Response to Leptospirosis for Better Diagnosis and Prognosis - NIHFI · NA · not yet recruiting
- NCT05821478 — Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients · Phase 3 · recruiting
- NCT06769815 — Host Immunity, Plasmodium and Pathogens Co-Infections · NA · not yet recruiting
- NCT06718127 — Description of the Immune Response to Yellow Fever Vaccination · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03326492 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut Pasteur
- Last refreshed: 22 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03326492.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing